Bio-Techne (TECH) Adds Julie L. Bushman to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Bio-Techne (TECH) Declares $0.32 Quarterly Dividend; 0.5% Yield
August 4, 2020 6:44 AM EDTBio-Techne (NASDAQ: TECH) declared a quarterly dividend of $0.32 per share, or $1.28 annualized.
The dividend will be payable on August 28, 2020, to stockholders of record on August 18, 2020, with an ex-dividend date of August 17, 2020.
The annual yield on the dividend is 0.5 percent.
For a... More
Bio-Techne (TECH) And Kantaro Biosciences To Launch A Quantitative Research Use Only COVID-19 Serology Test
August 3, 2020 7:07 AM EDTBio-Techne Corporation (NASDAQ: TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available for research use in early August.
The COVID-SeroIndex test kit is an enzyme-linked immunosorbent assay, or ELISA, designed to measure the presence or... More
